אדווקט לכלב וטרינרי ישראל - עברית - Ministry of Health

אדווקט לכלב וטרינרי

lidorr elements ltd - imidacloprid; moxidectin - תמיסה - imidacloprid 100 mg/ml; moxidectin 25 mg/ml - for dogs suffering from or at risk from mixed parasitic infections : for the treatment and prevention of flea infestation (ctenocephalides felis) treatment of biting lice (trichodectes canis) treatment of ear mit infestation (otodectes cynotis) sarcoptic mange (caused by sarcoptes scabiei var. canys) demodicosis ( caused by demodex canis) prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis) treatment of angiostrongylus vasorum adn treatment of infections with gastrointestinal nematodes (l4 larve immature adults and adults of toxocara canis ancylostoma caninum and uncinaria stenocephala adults of toxascaris leonina and trichuris vulpis). the product can be used as part of a treatment strategy for flea allergy dermatitis (fad).

אדווקט לחתולים וחמוסים וטרינרי ישראל - עברית - Ministry of Health

אדווקט לחתולים וחמוסים וטרינרי

lidorr elements ltd - imidacloprid; moxidectin - תמיסה - imidacloprid 100 mg/ml; moxidectin 10 mg/ml - cats:for cats suffering from or at risk from mixed parasitic infections : for the treatment and prevention of flea infestation (ctenocephalides felis) treatment of ear mit infestation (otodectes cynotis) prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis) and treatment of infections with gastrointestinal nematodes (l4 larve immature adults and adults of toxocara cati ancylostoma tubaeforne). the product can be used as part of a treatment strategy for flea allergy dermatitis (fad).ferrets:for ferrets suffering from, or at risk from, mixed parasitic infections : for the treatment and prevention of flea infestation (ctenocephalidas felis ) and the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis)

קרדיולייט ישראל - עברית - Ministry of Health

קרדיולייט

soreq nuclear research cent./ isorad - tetrakis copper - tetrafluoroborate - אבקה מיובשת בהקפאה להזרקה - tetrakis copper - tetrafluoroborate 1 mg/vial - combinations - combinations - myocardial imaging. prognostication. pharmacologic stress. breast imaging.

סטמיציס ישראל - עברית - Ministry of Health

סטמיציס

isorad ltd, israel - tetrakis copper (i) tetrafluoroborate - אבקה מיובשת בהקפאה להכנת תמיסה להזרקה - tetrakis copper (i) tetrafluoroborate 1 mg/vial

רוטה טק (חיסון חי פומי חמש ערכי נגד נגיף הרוטה) ישראל - עברית - Ministry of Health

רוטה טק (חיסון חי פומי חמש ערכי נגד נגיף הרוטה)

merck sharp & dohme (israel - 1996) company ltd, israel - rotavirus g1 reassortant; rotavirus g2 reassortant; rotavirus g3 reassortant; rotavirus g4 reassortant; rotavirus p1a[8] reassortant - suspension - rotavirus p1a[8] reassortant 2.3 x10 ^6 iu/dose; rotavirus g2 reassortant 2.8 x10 ^6 iu/dose; rotavirus g4 reassortant 2.0 x10^ 6 iu/dose; rotavirus g3 reassortant 2.2 x10 ^6 iu/dose; rotavirus g1 reassortant 2.2 x10 ^6 iu/dose - rota virus diarrhea vaccines - rotateq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes g1, g2, g3, and g4 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. the first dose of rorateq should be administered betwen 6 and 12 weeks of age.

קואט DVI 250 ישראל - עברית - Ministry of Health

קואט dvi 250

padagis israel agencies ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 250 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.

קואט DVI 500 ישראל - עברית - Ministry of Health

קואט dvi 500

padagis israel agencies ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 500 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.

קואט DVI 1000 ישראל - עברית - Ministry of Health

קואט dvi 1000

padagis israel agencies ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 1000 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.

גרדסיל ישראל - עברית - Ministry of Health

גרדסיל

merck sharp & dohme israel ltd - protein l1 (type 11); protein l1 (type 16); protein l1 (type 18); protein l1 (type 6) - תרחיף להזרקה - protein l1 (type 18) 20 mcg / 0.5 ml; protein l1 (type 6) 20 mcg / 0.5 ml; protein l1 (type 11) 40 mcg / 0.5 ml; protein l1 (type 16) 40 mcg / 0.5 ml - combinations - combinations - gardasil is indicated in females aged 9 through 45 years* for the prevention of cervical, vulvar, vaginal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16, and 18 (which are included in the vaccine). gardasil is indicated in males 9 through 26 years* of age for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infection caused by hpv types 6, 11, 16, and 18 (which are included in the vaccine). *immunogenicity studies have been conducted to link efficacy in females and males aged 16 to 26 years to the younger populations..

בוסטריקס ישראל - עברית - Ministry of Health

בוסטריקס

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); pertactin (prn or 69 kda omp); pertussis toxoid (pt); tetanus toxoid - תרחיף להזרקה - diphtheria toxoid nlt 2 iu / 0.5 ml; tetanus toxoid nlt 20 iu / 0.5 ml; filamentous haemagglutinin (fha) 8 mcg / 0.5 ml; pertussis toxoid (pt) 8 mcg / 0.5 ml; pertactin (prn or 69 kda omp) 2.5 mcg / 0.5 ml - tetanus toxoid, combinations with diphtheria toxoid - tetanus toxoid, combinations with diphtheria toxoid - for booster vaccination against diphtheria, tetanus and pertussis of individuals from the age of ten years onwards.